ALZN - CIK 0001677077
The table below shows Alzamend Neuro, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $1.41M | $6.46M | $7.45M | $5.20M | $1.31M | $1.07M |
| SG&A | $3.08M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $3.48M |
| $7.42M |
| $7.12M |
| $3.64M |
| $3.35M |
| Operating income | -$4.50M | -$9.94M | -$14.87M | -$12.32M | -$4.95M | -$4.42M |
| Income tax | - | - | - | - | - | - |
| Net income | -$4.51M | -$9.95M | -$14.88M | -$12.36M | -$5.05M | -$4.41M |
| EPS (diluted) | -$11.32 | -$132.33 | -$22.89 | -$0.14 | - | - |